BRPI0818865A2 - Anticorpos monoclonais contra proteína c ativada. - Google Patents

Anticorpos monoclonais contra proteína c ativada.

Info

Publication number
BRPI0818865A2
BRPI0818865A2 BRPI0818865A BRPI0818865A2 BR PI0818865 A2 BRPI0818865 A2 BR PI0818865A2 BR PI0818865 A BRPI0818865 A BR PI0818865A BR PI0818865 A2 BRPI0818865 A2 BR PI0818865A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
antibodies against
activated protein
against activated
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Jun Xu
Charles Esmon
Original Assignee
Oklahoma Med Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found filed Critical Oklahoma Med Res Found
Publication of BRPI0818865A2 publication Critical patent/BRPI0818865A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
BRPI0818865 2007-10-26 2008-10-24 Anticorpos monoclonais contra proteína c ativada. BRPI0818865A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Publications (1)

Publication Number Publication Date
BRPI0818865A2 true BRPI0818865A2 (pt) 2015-05-05

Family

ID=40289112

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818865 BRPI0818865A2 (pt) 2007-10-26 2008-10-24 Anticorpos monoclonais contra proteína c ativada.

Country Status (13)

Country Link
US (3) US8153766B2 (pt)
EP (1) EP2205638B1 (pt)
JP (3) JP2011500843A (pt)
KR (2) KR101856210B1 (pt)
CN (3) CN103232541A (pt)
AU (1) AU2008316661B2 (pt)
BR (1) BRPI0818865A2 (pt)
CA (1) CA2703738C (pt)
IL (2) IL205284A (pt)
MX (1) MX2010004615A (pt)
RU (2) RU2539729C2 (pt)
WO (1) WO2009055669A2 (pt)
ZA (1) ZA201105704B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107361011B (zh) * 2012-03-16 2021-08-27 瑞泽恩制药公司 制备表达ph敏感性免疫球蛋白序列的非人动物的方法
KR20150088869A (ko) * 2012-11-29 2015-08-03 바이엘 헬스케어 엘엘씨 활성화 단백질 C(aPC)에 대한 모노클로날 항체
SG11201504035PA (en) 2012-11-29 2015-06-29 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein c and uses thereof
US20160229922A1 (en) * 2013-09-20 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Treatment for hemorrhagic diseases by anti-protein-c antibody
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
WO2017087391A1 (en) * 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
CN117866097A (zh) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
TW201906868A (zh) * 2017-07-07 2019-02-16 日商第一三共股份有限公司 抗蛋白ｃ抗體
US20210355231A1 (en) * 2018-09-06 2021-11-18 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN115611986A (zh) 2021-07-13 2023-01-17 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US6989241B2 (en) * 2000-10-02 2006-01-24 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Also Published As

Publication number Publication date
IL205284A (en) 2014-06-30
WO2009055669A3 (en) 2009-09-03
EP2205638A2 (en) 2010-07-14
US20120164150A1 (en) 2012-06-28
AU2008316661A1 (en) 2009-04-30
RU2010121148A (ru) 2011-12-10
KR20150092358A (ko) 2015-08-12
MX2010004615A (es) 2010-07-06
AU2008316661B2 (en) 2013-05-23
JP2014237651A (ja) 2014-12-18
JP6117741B2 (ja) 2017-04-19
JP2013049694A (ja) 2013-03-14
RU2539729C2 (ru) 2015-01-27
IL205284A0 (en) 2010-12-30
RU2012150953A (ru) 2014-06-10
CN103232541A (zh) 2013-08-07
US20150344588A1 (en) 2015-12-03
ZA201105704B (en) 2014-05-28
US8153766B2 (en) 2012-04-10
WO2009055669A2 (en) 2009-04-30
KR20100116166A (ko) 2010-10-29
EP2205638B1 (en) 2017-03-01
IL220622A0 (en) 2012-08-30
US9127072B2 (en) 2015-09-08
CA2703738C (en) 2018-02-27
KR101856210B1 (ko) 2018-05-09
CN105153308A (zh) 2015-12-16
JP2011500843A (ja) 2011-01-06
CN101918453A (zh) 2010-12-15
US20090110683A1 (en) 2009-04-30
CA2703738A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0818865A2 (pt) Anticorpos monoclonais contra proteína c ativada.
CY2016030I2 (el) Αντισωματα εναντι της il-17
LTC2358756I2 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
BRPI0720218A2 (pt) Anticorpos monoclonais contra angptl3
BRPI0811907A2 (pt) Anticorpos monoclonais contra claudina-18 para tratamento de câncer.
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
NO344963B1 (no) Humanisert antistoff
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2225280T3 (da) Bivalente, bispecifikke antistoffer
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
DK2059533T3 (da) Multispecifikke antistoffer
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
BRPI0918947A2 (pt) proteína de fusão de anticorpo
BRPI0809677A2 (pt) Anticorpos anti-ige
BRPI0819165A2 (pt) Anticorpos anti-vegf
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK3656793T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
DOP2006000093A (es) Anticuerpos contra miostatina
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0923231A2 (pt) anticorpo anti-cmet.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2333 DE 22/09/2015

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]